Sang Hui Jo

Title: The Innovations of Sang Hui Jo

Introduction

Sang Hui Jo is a notable inventor based in Daejeon, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of anticoagulant therapies. With a focus on innovative compounds, his work has the potential to impact the treatment of thromboembolism and tumors.

Latest Patents

Sang Hui Jo holds 2 patents that showcase his expertise in medicinal chemistry. His latest patents include:

1. FXa inhibitors with cyclic amidines as P4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof. This invention relates to novel oxazolidinone derivatives with cyclic amidines, which can be used as anticoagulants for treating thromboembolism and tumors via inhibition of coagulation factor Xa.

2. FXA inhibitors with cyclic amidoxime or cyclic amidrazone as P4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof. This patent discloses novel oxazolidinone derivatives that can effectively treat thromboembolism and tumors based on the inhibition of factor Xa.

Career Highlights

Sang Hui Jo is currently employed at Legochem Bioscience Ltd., where he continues to advance his research in pharmaceutical innovations. His work is characterized by a commitment to developing effective treatments that address critical health issues.

Collaborations

Throughout his career, Sang Hui Jo has collaborated with notable colleagues, including Ho Young Song and Young Lag Cho. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Sang Hui Jo's contributions to the field of pharmaceuticals through his innovative patents highlight his role as a leading inventor. His work in developing new anticoagulant therapies demonstrates the potential for significant advancements in medical treatments.